Inmagenebio
Founded 2019 · 50 employees on LinkedIn · 2 known investors
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases. Its lead candidate, IMG-007, is an extended half-life anti-OX40 monoclonal antibody that inhibits OX40 receptor signaling without depleting T cells.
Investors · 2
Frequently asked questions
- What does Inmagenebio do?
- ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases. Its lead candidate, IMG-007, is an extended half-life anti-OX40 monoclonal antibody that inhibits OX40 receptor signaling without depleting T cells.
- Who are Inmagenebio's investors?
- Inmagenebio's investors include G Vision Capital, Vertex Ventures China.